Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus TRIPROLIDINE AND PSEUDOEPHEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus TRIPROLIDINE AND PSEUDOEPHEDRINE.
BENADRYL PRESERVATIVE FREE vs TRIPROLIDINE AND PSEUDOEPHEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
Triprolidine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing histamine-mediated allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and decreased nasal congestion.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
1 tablet (2.5 mg triprolidine/60 mg pseudoephedrine) orally every 4-6 hours; max 4 tablets/24 hours.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Triprolidine: 2-4 hours (parent compound). Pseudoephedrine: 4-8 hours, prolonged in alkaline urine (up to 16-24 hours).
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Triprolidine: renal, 70% unchanged and metabolites. Pseudoephedrine: renal, 90% unchanged.
Category C
Category A/B
Antihistamine
Antihistamine